Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study.
María Ángeles Sánchez-DuránAndrea Bernabeu GarcíaInés CaleroJordi Ramis FossasTamara IllescasMaría Teresa AvilésNerea MaízElena CarrerasPublished in: BMC pregnancy and childbirth (2019)
A contingent screening strategy for trisomies 21, 18 and 13, based on conventional screening, and offering a cfDNA test to women with a risk between 1:11 to 1:1500, reduced the false positive rate and increased the detection rate for these trisomies. Moreover, this strategy is well accepted by women.